MCID: FNC027
MIFTS: 73

Fanconi Anemia, Complementation Group a malady

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Bone diseases, Skin diseases, Fetal diseases, Blood diseases

Aliases & Classifications for Fanconi Anemia, Complementation Group a

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 23GeneReviews, 24GeneTests, 25Genetics Home Reference, 26GTR, 29ICD10, 30ICD10 via Orphanet, 34LifeMap Discovery®, 36MedGen, 38MeSH, 39MESH via Orphanet, 44NCIt, 47NIH Rare Diseases, 49Novoseek, 51OMIM, 53Orphanet, 61SNOMED-CT, 67UMLS, 68UMLS via Orphanet, 69UniProtKB/Swiss-Prot, 70Wikipedia
See all MalaCards sources

Aliases & Descriptions for Fanconi Anemia, Complementation Group a:

Name: Fanconi Anemia, Complementation Group a 51 69 26 12 34 67
Fanconi Anemia 11 70 23 47 24 25 53 69 26 38 13 67
Fanconi Pancytopenia 11 23 47 24 25 53
Fanconi's Anemia 34 11 47 13
Fa 70 25 69
Fanconi Panmyelopathy 11 25
 
Estren-Dameshek Variant of Fanconi Pancytopenia 69
Estren-Dameshek Variant of Fanconi Anemia 69
Fanconi Anemia Estren-Dameshek Variant 69
Fanconi Hypoplastic Anemia 25
Fanconis Anemia 49
Fanca 69

Characteristics:

Orphanet epidemiological data:

53
fanconi anemia:
Inheritance: Autosomal recessive,X-linked recessive; Prevalence: 1-9/1000000 (Europe); Age of onset: Childhood

Classifications:



External Ids:

OMIM51 227650
Disease Ontology11 DOID:13636
ICD1029 D61.09
MeSH38 D005199
NCIt44 C62505
SNOMED-CT61 30575002
Orphanet53 ORPHA84
MESH via Orphanet39 D005199
ICD10 via Orphanet30 D61.0
UMLS via Orphanet68 C0015625

Summaries for Fanconi Anemia, Complementation Group a

About this section
OMIM:51 Fanconi anemia is a clinically and genetically heterogeneous disorder that causes genomic instability. Characteristic... (227650) more...

MalaCards based summary: Fanconi Anemia, Complementation Group a, also known as fanconi anemia, is related to familial breast cancer and microphthalmia, and has symptoms including hypopigmented skin patches, thrombocytopenia and leukopenia. An important gene associated with Fanconi Anemia, Complementation Group a is FANCA (Fanconi Anemia Complementation Group A), and among its related pathways are DNA Damage Induced 14-3-3Sigma Signaling and DNA damage_ATM/ATR regulation of G1/S checkpoint. Affiliated tissues include bone, bone marrow and kidney, and related mouse phenotypes are embryo and neoplasm.

Disease Ontology:11 A congenital hypoplastic anemia characterized by progressive pancytopenia with bone marrow failure, variable congenital malformations and predisposition to develop hematological or solid tumors. It is a result of a genetic defect in a cluster of proteins responsible for DNA repair.

UniProtKB/Swiss-Prot:69 Fanconi anemia, complementation group A: A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.

Genetics Home Reference:25 Fanconi anemia is a condition that affects many parts of the body. People with this condition may have bone marrow failure, physical abnormalities, organ defects, and an increased risk of certain cancers.

NIH Rare Diseases:47 Fanconi anemia is an inherited condition that affects the bone marrow, resulting in decreased production of all types of blood cells. People with this condition have lower-than-normal numbers of white blood cells, red blood cells, and platelets (cells that help the blood clot). Not enough white blood cells can lead to infections; a lack of red blood cells may result in anemia; and a decreased amount of platelets may lead to excess bleeding. Fanconi anemia can be caused by mutations in various genes; it can either be inherited in an autosomal recessive, autosomal dominant or X-linked recessive fashion. Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for the blood problems. Genetics Home Reference have information about Fanconi Anemia. Last updated: 12/13/2016

GeneReviews for NBK1401

Related Diseases for Fanconi Anemia, Complementation Group a

About this section

Diseases in the Fanconi Anemia, Complementation Group T family:

Fanconi Anemia, Complementation Group L Fanconi Anemia, Complementation Group I
Fanconi Anemia, Complementation Group P Fanconi Anemia, Complementation Group Q
Fanconi Anemia, Complementation Group N fanconi anemia, complementation group a
Fanconi Anemia, Complementation Group J Fanconi Anemia, Complementation Group O

Diseases related to Fanconi Anemia, Complementation Group a via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 148)
idRelated DiseaseScoreTop Affiliating Genes
1familial breast cancer31.1BRCA1, BRCA2, PALB2
2microphthalmia30.6FANCA, FANCC, FANCD2, FANCG, FANCI, FANCL
3fanconi anemia, complementation group c12.4
4fanconi anemia, complementation group f12.4
5fanconi anemia, complementation group e12.3
6fanconi anemia, complementation group i12.3
7fanconi anemia, complementation group b12.3
8fanconi anemia, complementation group j12.3
9fanconi anemia, complementation group d212.3
10fanconi anemia, complementation group p12.3
11fanconi anemia, complementation group l12.2
12fanconi anemia, complementation group g12.2
13fanconi anemia, complementation group d112.2
14fanconi anemia, complementation group q12.2
15fanconi anemia, complementation group n12.2
16fanconi anemia, complementation group o12.2
17fanconi anemia, complementation group t12.2
18ercc4-related fanconi anemia11.9
19ube2t-related fanconi anemia11.9
20brca2-related fanconi anemia11.8
21brip1-related fanconi anemia11.8
22fanca-related fanconi anemia11.8
23fancb-related fanconi anemia11.8
24fancc-related fanconi anemia11.8
25fancd2-related fanconi anemia11.8
26fance-related fanconi anemia11.8
27fancf-related fanconi anemia11.8
28fancg-related fanconi anemia11.8
29fanci-related fanconi anemia11.8
30fancl-related fanconi anemia11.8
31fancm-related fanconi anemia11.8
32palb2-related fanconi anemia11.8
33rad51c-related fanconi anemia11.8
34slx4-related fanconi anemia11.8
35fas-related autoimmune lymphoproliferative syndrome11.8
36autoimmune lymphoproliferative syndrome11.6
37warsaw breakage syndrome11.3
38friedreich ataxia11.3
39aplastic anemia11.2
40fetal alcohol syndrome11.1
41vater association with macrocephaly and ventriculomegaly11.1
42fanconi renotubular syndrome 111.0
43fetal alcohol spectrum disorder11.0
44congenital pulmonary veins atresia or stenosis10.9BRCA1, BRCA2
45secondary hyperparathyroidism of renal origin10.9FANCA, FANCC, FANCG
46fgfr-related craniosynostosis syndromes10.9FANCI, FANCL, FANCM
47thrombocytopenia-absent radius syndrome10.9
48congenital hypoplastic anemia10.9
49bronchopulmonary dysplasia10.8BRCA1, BRCA2
50cutaneous lupus erythematosus10.8BRCA1, BRCA2

Graphical network of the top 20 diseases related to Fanconi Anemia, Complementation Group a:



Diseases related to fanconi anemia, complementation group a

Symptoms for Fanconi Anemia, Complementation Group a

About this section

Symptoms by clinical synopsis from OMIM:

227650

Clinical features from OMIM:

227650

Human phenotypes related to Fanconi Anemia, Complementation Group a:

 63 53 (show all 136)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypopigmented skin patches63 53 hallmark (90%) Very frequent (99-80%) HP:0001053
2 thrombocytopenia63 53 hallmark (90%) Very frequent (99-80%) HP:0001873
3 leukopenia63 53 hallmark (90%) Very frequent (99-80%) HP:0001882
4 anemia63 53 hallmark (90%) Very frequent (99-80%) HP:0001903
5 abnormality of chromosome stability63 53 hallmark (90%) Very frequent (99-80%) HP:0003220
6 short stature63 53 hallmark (90%) Very frequent (99-80%) HP:0004322
7 bone marrow hypocellularity63 hallmark (90%) HP:0005528
8 aplasia/hypoplasia of the radius63 53 hallmark (90%) Very frequent (99-80%) HP:0006501
9 irregular hyperpigmentation63 53 hallmark (90%) Very frequent (99-80%) HP:0007400
10 microcephaly63 53 typical (50%) Frequent (79-30%) HP:0000252
11 blepharophimosis63 typical (50%) HP:0000581
12 scoliosis63 53 typical (50%) Frequent (79-30%) HP:0002650
13 cognitive impairment63 typical (50%) HP:0100543
14 abnormality of female internal genitalia63 occasional (7.5%) HP:0000008
15 recurrent urinary tract infections63 53 occasional (7.5%) Occasional (29-5%) HP:0000010
16 functional abnormality of male internal genitalia63 occasional (7.5%) HP:0000025
17 cryptorchidism63 53 occasional (7.5%) Occasional (29-5%) HP:0000028
18 renal insufficiency63 53 occasional (7.5%) Occasional (29-5%) HP:0000083
19 cleft palate63 53 occasional (7.5%) Occasional (29-5%) HP:0000175
20 hydrocephalus63 53 occasional (7.5%) Occasional (29-5%) HP:0000238
21 dolichocephaly63 53 occasional (7.5%) Occasional (29-5%) HP:0000268
22 epicanthus63 53 occasional (7.5%) Occasional (29-5%) HP:0000286
23 hypertelorism63 53 occasional (7.5%) Occasional (29-5%) HP:0000316
24 facial asymmetry63 53 occasional (7.5%) Occasional (29-5%) HP:0000324
25 sloping forehead63 53 occasional (7.5%) Occasional (29-5%) HP:0000340
26 micrognathia63 53 occasional (7.5%) Occasional (29-5%) HP:0000347
27 hearing impairment63 53 occasional (7.5%) Occasional (29-5%) HP:0000365
28 choanal atresia63 53 occasional (7.5%) Occasional (29-5%) HP:0000453
29 astigmatism63 53 occasional (7.5%) Occasional (29-5%) HP:0000483
30 strabismus63 53 occasional (7.5%) Occasional (29-5%) HP:0000486
31 visual impairment63 53 occasional (7.5%) Occasional (29-5%) HP:0000505
32 ptosis63 53 occasional (7.5%) Occasional (29-5%) HP:0000508
33 cataract63 53 occasional (7.5%) Occasional (29-5%) HP:0000518
34 proptosis63 53 occasional (7.5%) Occasional (29-5%) HP:0000520
35 upslanted palpebral fissure63 53 occasional (7.5%) Occasional (29-5%) HP:0000582
36 nystagmus63 53 occasional (7.5%) Occasional (29-5%) HP:0000639
37 abnormality of the hypothalamus-pituitary axis63 53 occasional (7.5%) Occasional (29-5%) HP:0000864
38 cafe-au-lait spot63 occasional (7.5%) HP:0000957
39 triphalangeal thumb63 53 occasional (7.5%) Occasional (29-5%) HP:0001199
40 hyperreflexia63 53 occasional (7.5%) Occasional (29-5%) HP:0001347
41 abnormality of the liver63 53 occasional (7.5%) Occasional (29-5%) HP:0001392
42 intrauterine growth retardation63 53 occasional (7.5%) Occasional (29-5%) HP:0001511
43 umbilical hernia63 53 occasional (7.5%) Occasional (29-5%) HP:0001537
44 oligohydramnios63 53 occasional (7.5%) Occasional (29-5%) HP:0001562
45 atria septal defect63 occasional (7.5%) HP:0001631
46 tetralogy of fallot63 53 occasional (7.5%) Occasional (29-5%) HP:0001636
47 hypertrophic cardiomyopathy63 53 occasional (7.5%) Occasional (29-5%) HP:0001639
48 patent ductus arteriosus63 53 occasional (7.5%) Occasional (29-5%) HP:0001643
49 abnormality of the aortic valve63 53 occasional (7.5%) Occasional (29-5%) HP:0001646
50 abnormality of the aorta63 53 occasional (7.5%) Occasional (29-5%) HP:0001679
51 pes planus63 53 occasional (7.5%) Occasional (29-5%) HP:0001763
52 toe syndactyly63 53 occasional (7.5%) Occasional (29-5%) HP:0001770
53 weight loss63 53 occasional (7.5%) Occasional (29-5%) HP:0001824
54 frontal bossing63 53 occasional (7.5%) Occasional (29-5%) HP:0002007
55 ventriculomegaly63 53 occasional (7.5%) Occasional (29-5%) HP:0002119
56 meckel diverticulum63 53 occasional (7.5%) Occasional (29-5%) HP:0002245
57 aganglionic megacolon63 53 occasional (7.5%) Occasional (29-5%) HP:0002251
58 spina bifida63 53 occasional (7.5%) Occasional (29-5%) HP:0002414
59 tracheoesophageal fistula63 53 occasional (7.5%) Occasional (29-5%) HP:0002575
60 abnormality of the femur63 53 occasional (7.5%) Occasional (29-5%) HP:0002823
61 myelodysplasia63 53 occasional (7.5%) Occasional (29-5%) HP:0002863
62 abnormality of the ulna63 53 occasional (7.5%) Occasional (29-5%) HP:0002997
63 abnormality of the hip bone63 occasional (7.5%) HP:0003272
64 clinodactyly of the 5th finger63 53 occasional (7.5%) Occasional (29-5%) HP:0004209
65 reduced bone mineral density63 53 occasional (7.5%) Occasional (29-5%) HP:0004349
66 abnormality of the carotid arteries63 53 occasional (7.5%) Occasional (29-5%) HP:0005344
67 finger syndactyly63 53 occasional (7.5%) Occasional (29-5%) HP:0006101
68 cranial nerve paralysis63 53 occasional (7.5%) Occasional (29-5%) HP:0006824
69 aplasia/hypoplasia of the iris63 53 occasional (7.5%) Occasional (29-5%) HP:0008053
70 external ear malformation63 53 occasional (7.5%) Occasional (29-5%) HP:0008572
71 renal hypoplasia/aplasia63 53 occasional (7.5%) Occasional (29-5%) HP:0008678
72 aplasia/hypoplasia of the uvula63 53 occasional (7.5%) Occasional (29-5%) HP:0010293
73 arteriovenous malformation63 53 occasional (7.5%) Occasional (29-5%) HP:0100026
74 abnormal localization of kidney63 53 occasional (7.5%) Occasional (29-5%) HP:0100542
75 abnormality of the preputium63 53 occasional (7.5%) Occasional (29-5%) HP:0100587
76 urogenital fistula63 occasional (7.5%) HP:0100589
77 displacement of the external urethral meatus63 occasional (7.5%) HP:0100627
78 clubbing of toes63 53 occasional (7.5%) Occasional (29-5%) HP:0100760
79 duodenal stenosis63 53 occasional (7.5%) Occasional (29-5%) HP:0100867
80 duplicated collecting system63 HP:0000081
81 horseshoe kidney63 HP:0000085
82 ectopic kidney63 HP:0000086
83 renal agenesis63 HP:0000104
84 microphthalmia63 53 Occasional (29-5%) HP:0000568
85 hypergonadotropic hypogonadism63 HP:0000815
86 bruising susceptibility63 HP:0000978
87 abnormality of skin pigmentation63 53 Very frequent (99-80%) HP:0001000
88 anemic pallor63 HP:0001017
89 intellectual disability63 53 Frequent (79-30%) HP:0001249
90 small for gestational age63 HP:0001518
91 neutropenia63 HP:0001875
92 pancytopenia63 HP:0001876
93 reticulocytopenia63 HP:0001896
94 leukemia63 HP:0001909
95 deficient excision of uv-induced pyrimidine dimers in dna63 HP:0003213
96 prolonged g2 phase of cell cycle63 HP:0003214
97 chromosomal breakage induced by crosslinking agents63 HP:0003221
98 absent radius63 HP:0003974
99 absent thumb63 HP:0009777
100 short thumb63 HP:0009778
101 complete duplication of thumb phalanx63 HP:0009943
102 abnormality of cardiovascular system morphology63 HP:0030680
103 azoospermia53 Occasional (29-5%)
104 abnormality of the testis53 Occasional (29-5%)
105 hypospadias53 Occasional (29-5%)
106 hydroureter53 Occasional (29-5%)
107 abnormality of the urinary system53 Frequent (79-30%)
108 abnormality of the uterus53 Occasional (29-5%)
109 hypogonadism53 Occasional (29-5%)
110 high palate53 Occasional (29-5%)
111 hearing abnormality53 Occasional (29-5%)
112 abnormality of the eye53 Occasional (29-5%)
113 abnormality of the eyelid53 Occasional (29-5%)
114 abnormality of vision53 Occasional (29-5%)
115 bicornuate uterus53 Occasional (29-5%)
116 abnormality of the thumb53 Very frequent (99-80%)
117 global developmental delay53 Frequent (79-30%)
118 growth delay53 Occasional (29-5%)
119 defect in the atrial septum53 Occasional (29-5%)
120 abnormality of the cardiac septa53 Frequent (79-30%)
121 abnormality of the foot53 Occasional (29-5%)
122 abnormality of blood and blood-forming tissues53 Very frequent (99-80%)
123 anal atresia53 Occasional (29-5%)
124 neoplasm53 Frequent (79-30%)
125 abnormality of the upper limb53 Very frequent (99-80%)
126 hip dislocation53 Occasional (29-5%)
127 hypoplasia of the ulna53 Occasional (29-5%)
128 pyridoxine-responsive sideroblastic anemia53 Very frequent (99-80%)
129 aplasia/hypoplasia of fingers53 Occasional (29-5%)
130 multiple cafe-au-lait spots53 Occasional (29-5%)
131 almond-shaped palpebral fissure53 Frequent (79-30%)
132 aplasia of the testes53 Occasional (29-5%)
133 decreased fertility in males53 Occasional (29-5%)
134 abnormal renal morphology53 Frequent (79-30%)
135 abnormality of nervous system morphology53 Occasional (29-5%)
136 short palpebral fissure53 Frequent (79-30%)

Drugs & Therapeutics for Fanconi Anemia, Complementation Group a

About this section

Drugs for Fanconi Anemia, Complementation Group a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 101)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
VidarabineapprovedPhase 2, Phase 3, Phase 1, Early Phase 151224356-66-932326, 21704
Synonyms:
(+)-Cyclaradine
.beta.-Adenosine
.beta.-D-Adenosine
1odi
2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
2946-52-3
2fqy
2gl0
30143-02-3
3080-29-3
3228-71-5
4005-33-8
46946-45-6
46969-16-8
524-69-6
5536-17-4
58-61-7
9-Arabinosyladenine
9-beta-D-Arabinofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyl-adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-arabinofuranosyl-adenine
9-β-D-arabinofuranosyl-9H-purin-6-amine
9-β-D-arabinofuranosyladenine
A 9251
A0152
A4036_SIGMA
A4676_SIGMA
A5762_SIGMA
A9251_SIGMA
AC1L18OL
AC1L1U8O
AC1L2IWM
AC1L2SCM
AC1O4WIN
AC1O8PY7
AC1Q1ID3
AC1Q4Y1Z
AC1Q52XU
ADENOSINE, U.S.P.
ADN
AI3-52413
AI3-52821
AR-1H6029
ARA-A NSC 247519
Ade-Rib
Adenine Arabinoside
Adenine arabinoside
Adenine nucleoside
Adenine riboside
Adenine xyloside
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine arabinose
Adenosine-8-14C
Adensoine
Ambap5536-17-4
Ara A
Ara-A
Ara-ATP
Araadenosine
Arabinoside Adenine
Arabinoside adenine
Arabinosyl Adenine
Arabinosyl adenine
Arabinosyl-adenine
Arabinosyladenine
Arasena-A
Armes
Armes (TN)
BB_NC-0565
BPBio1_000898
BRN 0624881
BSPBio_000816
BSPBio_001796
BSPBio_002000
Bio1_000437
Bio1_000926
Bio1_001415
Boniton
C00212
CAS-5536-17-4
CCRIS 2557
CCRIS 3383
CHEBI:136932
CHEBI:16335
CHEBI:45327
CHEMBL1090
CHEMBL20247
CHEMBL477
CI 673
CI-673
CID102198
CID191
CID21704
CID60961
CID6420052
CID6713976
CPD000471872
Caswell No. 010B
D000241
D00045
D06298
DB00640
DivK1c_000191
EINECS 200-389-9
EINECS 217-911-6
EINECS 226-893-9
EU-0100123
FT-0082881
HMS1570I18
HMS1920A13
HMS1921K05
HMS2090F06
HMS2091G13
HMS2092C16
HMS500J13
HSDB 6514
 
I01-1121
IDI1_000191
KBio1_000191
KBio2_002418
KBio2_004986
KBio2_007554
KBio3_001296
KBio3_001500
KBioGR_001224
KBioSS_002424
L000094
LS-15059
LS-15085
Lopac0_000123
MEDR-640
MLS000069638
MLS000699527
MLS001066352
MLS001333133
MLS001333134
MLS002153227
MLS002153992
MolPort-001-785-903
MolPort-001-838-229
MolPort-003-666-308
Myocol
NCGC00016656-01
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NCGC00094579-01
NCGC00094579-02
NCGC00094579-03
NCGC00094579-04
NCGC00178869-01
NCGC00179417-01
NCI60_003823
NCI60_037192
NCIOpen2_003303
NCIOpen2_005376
NINDS_000191
NSC 247519
NSC 404241
NSC 627048
NSC 7359
NSC 7652
NSC-404241
NSC247519
NSC404241
NSC627048
NSC70422
NSC7359
NSC7652
NSC80832
NSC87676
NSC91041
Nucleocardyl
PDSP1_001036
PDSP2_001020
Pallacor
Polyadenosine
Polyriboadenosine
Prestwick0_000768
Prestwick1_000768
Prestwick2_000768
Prestwick3_000768
Prestwick_983
RAB
S1647_Selleck
S1784_Selleck
SAM002564191
SMP1_000312
SMR000058216
SMR000225041
SMR000471872
SMR001233326
SPBio_001194
SPBio_001491
SPBio_002755
SPECTRUM1500107
SPECTRUM1500609
SR 96225
SR-96225
STK361815
SUN-Y4001
Sandesin
Spectrum2_001257
Spectrum2_001336
Spectrum3_000288
Spectrum3_000580
Spectrum4_000782
Spectrum5_001429
Spectrum_001894
Spongoadenosine
TL8003749
UNII-3XQD2MEW34
UNII-K72T3FS567
USAF CB-10
V0098
VIRDARABINE
Vidarabin
Vidarabina
Vidarabina [DCIT]
Vidarabine
Vidarabine (JAN)
Vidarabine anhydrous
Vidarabinum
Vira ATM
Vira-A
Vira-A, Vidarabine
XA
Xylosyl A
Xylosyladenine
ZINC00970363
ZINC02169830
adenine-D-ribose
adenosine
alpha-Ara A
beta-Adenosine
beta-Ara A
beta-D-Adenosine
bmse000061
nchembio.143-comp9
nchembio.186-comp109
nchembio.64-comp4
nchembio706-5
2
Busulfanapproved, investigationalPhase 2, Phase 3, Phase 1, Early Phase 154055-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
3
Cyclophosphamideapproved, investigationalPhase 2, Phase 3, Phase 1, Early Phase 1282950-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
4
FludarabineapprovedPhase 2, Phase 3, Phase 1, Early Phase 1111321679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ARAA
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-fluoro ARA-A
21679-14-1
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
Fludara, Fludarabine
 
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
5
alemtuzumabapproved, investigationalPhase 2, Phase 3, Phase 1303216503-57-0
Synonyms:
Campath
 
MabCampath
alemtuzumab
6
Cysteamineapproved, investigationalPhase 3, Phase 1, Phase 22760-23-16058
Synonyms:
(2-Mercaptoethyl)amine
(Mercaptoethyl)ammonium toluene-p-sulphonate
.beta.-Mercaptoethylamine
1-Amino-2-mercaptoethylamine
139720-70-0
156-57-0 (hydrochloride)
16904-32-8 (di-hydrochloride)
2-AMINO-ETHANETHIOL
2-AMINO-ethanethiol
2-Amino-1-ethanethiol
2-Aminoethanethiol
2-Aminoethyl mercaptan
2-Mercaptoethanamine
2-Mercaptoethylamine
2-Mercaptoethylamine, polymer-bound
27761-19-9 (tartrate (1:1))
2DFDA1F8-7010-4225-8280-AB1C4C43F546
30070_FLUKA
30070_SIGMA
3037-04-5
3037-04-5 (tosylate)
42954-15-4 (hydrobromide)
60-23-1
60-23-1 (Parent)
641022_ALDRICH
93965-19-6 (maleate (1:1))
A0648
AC1L1LPL
AC1Q54NL
AKOS003793343
Aminoethyl mercaptan
Becaptan
C-9500
C01678
C2H7NS
CASH
CCRIS 3083
CHEBI:17141
CHEMBL602
CID6058
CYSTEAMINE
Cisteamina
Cisteamina [Italian]
Cystavision
Cysteamide
Cysteamin
Cysteamine
Cysteamine (USAN)
Cysteamine [USAN:BAN]
Cysteamine bitartate
Cysteamine hydrochloride
Cysteaminium
Cysteinamine
D03634
DB00847
Decarboxycysteine
DivK1c_006750
 
EINECS 200-463-0
EINECS 221-235-7
Ethanethiolamine
HSDB 7353
KBio1_001694
KBio2_002235
KBio2_004803
KBio2_007371
KBioSS_002235
L 1573
L-1573
LS-65761
Lambraten
Lambratene
Lopac-M-6500
M9768_ALDRICH
M9768_SIGMA
MEA
MEA (mercaptan)
Mecramine
Mercamin
Mercamine
Mercaptamin
Mercaptamina
Mercaptamina [INN-Spanish]
Mercaptamine
Mercaptamine (INN)
Mercaptaminum
Mercaptaminum [INN-Latin]
Mercaptoethylamine
Merkamin
MolPort-001-662-635
NCGC00015691-01
NCGC00015691-04
NCGC00162236-01
NCI60_002000
NSC 647528
NSC647528
Riacon
STK315355
SpecPlus_000654
Spectrum_001755
Thioethanolamine
UNII-5UX2SD1KE2
WR 347
b-Aminoethanethiol
b-Aminoethylthiol
b-Mercaptoethylamine
beta-Aminoethanethiol
beta-Aminoethylthiol
beta-MEA
beta-Mercaptoethylamine
bmse000388
cysteamine bitartrate
nchembio.315-comp1
nchembio.316-comp1
β-MEA
β-aminoethylthiol
7
Deferasiroxapproved, investigationalPhase 3, Phase 289201530-41-85493381
Synonyms:
Deferasiroxum
Deferasiroxum [inn-latin]
 
Exjade
ICL 670
ICL 670a
deferasirox
8
Miconazoleapproved, investigational, vet_approvedPhase 2, Phase 3, Phase 1362422916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
9
IronapprovedPhase 3, Phase 211237439-89-623925
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
ATW 230
ATW 432
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
C00023
C3518_SIAL
C3518_SIGMA
CCRIS 1580
CHEBI:18248
CID23925
Carbonyl iron
Copy Powder CS 105-175
D007501
DB01592
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Diseases (animal), iron overload
Diseases, iron overload
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
 
Ed-In-Sol
Eisen
Electrolytic iron
F 60 (metal)
FE
FT 3 (element)
Fe
Fe-40
Fe1+
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrousal
Ferrovac E
Ferrum
Ferrum metallicum
GS 6
HF 2 (element)
HL (iron)
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Hemocyte
Hierro
Hoeganaes ATW 230
Hoeganaes EH
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh-1M3
PZh-2
PZh1M1
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Reduced iron
Remko
SUY-B 2
Siderol
UNII-E1UOL152H7
Vitedyn-Slo
Yieronia
fer
ferrous iron
hierro
10
Sirolimusapproved, investigationalPhase 2, Phase 3189653123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
11
Mycophenolate mofetilapproved, investigationalPhase 2, Phase 3, Phase 1939128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
12
Mycophenolic acidapprovedPhase 2, Phase 3, Phase 193924280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
13
EverolimusapprovedPhase 2, Phase 31896159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
14AntimetabolitesPhase 2, Phase 3, Phase 1, Early Phase 111774
15Anti-Infective AgentsPhase 2, Phase 3, Phase 1, Early Phase 121402
16Immunosuppressive AgentsPhase 2, Phase 3, Phase 1, Early Phase 112770
17Alkylating AgentsPhase 2, Phase 3, Phase 1, Early Phase 14694
18Antineoplastic Agents, AlkylatingPhase 2, Phase 3, Phase 1, Early Phase 14474
19Antimetabolites, AntineoplasticPhase 2, Phase 3, Phase 1, Early Phase 17171
20Antirheumatic AgentsPhase 2, Phase 3, Phase 1, Early Phase 110627
21Antiviral AgentsPhase 2, Phase 3, Phase 1, Early Phase 19732
22Chelating AgentsPhase 3, Phase 21365
23Iron Chelating AgentsPhase 3, Phase 2222
24Antifungal AgentsPhase 2, Phase 3, Phase 13615
25Anti-Bacterial AgentsPhase 2, Phase 3, Phase 110884
26Antibiotics, AntitubercularPhase 2, Phase 3, Phase 16972
27
LenograstimapprovedPhase 1, Phase 21202135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
28
MelphalanapprovedPhase 2, Phase 1712148-82-34053, 460612
Synonyms:
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
148-82-3
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3025 C.B.
3025 c.b
3223-07-2
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
AC1LA2OE
ALKERAN (TN)
AY3360000
Alanine Nitrogen Mustard
Alkeran
AmbotzHAA1563
At-290
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
L-PAM
L-Phenylalanine mustard
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
LS-15868
LS-865
 
Levofalan
Levofolan
Levopholan
M2011_SIGMA
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
MLS001333666
MLS002153368
Melfalan
Melfalano
Melfalano [INN-Spanish]
Melphalan (JP15/USP/INN)
Melphalan [USAN:INN:BAN:JAN]
Melphalanum
Melphalanum [INN-Latin]
Mephalan
MolPort-003-665-535
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC-8806
NSC241286
NSC8806
P-Di-(2-chloroethyl)amino-L-phenylalanine
P-L-Sarcolysin
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
SPECTRUM1500382
Sarcolysine
Sarkolysin
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
Spectrum_000397
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
melphalan
p-Bis(beta-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
p-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Di(chloroethyl)aminophenylalanine
p-N-di(chloroethyl)aminophenylala nine
phenylalanine nitrogen mu stard
29
Methylprednisoloneapproved, vet_approvedPhase 2, Phase 1115383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
30
Prednisoloneapproved, vet_approvedPhase 2, Phase 1115350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
31
Cyclosporineapproved, investigational, vet_approvedPhase 1, Phase 291579217-60-0, 59865-13-35284373, 6435893
Synonyms:
1c5f
1cyn
30024_FLUKA
30024_SIGMA
59865-13-3
79217-60-0
AC1L1EQW
AC1NQXJE
AC1NR4C4
AC1NUQK3
AC1NUZNC
AC1O5KOG
AC1Q2UDG
Ambap59865-13-3
Ambotz59865-13-3
Antibiotic S 7481F1
BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA
BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA
BPBio1_000496
BRD-A64290322-001-01-6
BRD-A69815203-001-04-3
BRD-K13533483-001-03-0
BSPBio_000450
BSPBio_001596
BSPBio_003186
C 3662
C05086
C1832_SIGMA
C3662_SIGMA
C62H111N11O12
CB-01-09 MMX
CHEBI:106343
CHEBI:328305
CHEBI:4031
CHEMBL160
CHEMBL386389
CHEMBL532318
CID2909
CID5280754
CID5284373
CID5458585
CID5497195
CID6435893
CSA
CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A))
CYCLOSPORIN A, USP
Ciclosporin
Ciclosporin (JP15)
Ciclosporina
Ciclosporine
Ciclosporinum
Cipol N
Cipol-N
Consupren
Consupren S
CsA
CsA & IFN.alpha.
CyA
Cyclokat
Cyclosporin
Cyclosporin A
Cyclosporin A & IFN.alpha.
Cyclosporin A Implant
Cyclosporin A, Tolypocladium inflatum
Cyclosporine (USP)
Cyclosporine A
Cyclosporine [USAN]
D00184
DE-076
DivK1c_000871
EU-0100242
Equoral
GNF-Pf-2808
Gengraf
Gengraf (TN)
HMS1569G12
HMS1791P18
HMS1921L20
HMS1989P18
HMS2089A09
HMS2092F06
HMS502L13
Helv Chim Acta 60: 1568 (1977)
 
I06-0379
I06-0966
IDI1_000871
KBio1_000871
KBio2_000780
KBio2_003348
KBio2_005916
KBio3_002686
KBioGR_001898
KBioSS_000780
LMPK14000003
LS-257
LS-58836
Lopac0_000242
MLS000028376
MLS001333756
MLS002153454
MLS002207033
Mitogard
Modusik-A
MolPort-000-760-988
MolPort-005-934-008
MolPort-006-705-994
NCGC00093704-01
NCGC00093704-02
NCGC00093704-03
NCGC00093704-04
NCGC00093704-05
NCGC00093704-06
NCGC00093704-07
NCGC00093704-08
NCGC00164258-01
NCGC00164258-02
NINDS_000871
NSC290193
Neoplanta
Neoral
Neoral (TN)
NeuroSTAT
Nova-22007
OL 27-400
OL-27400
OLO-400
Papilock
Prestwick2_000435
Prestwick3_000435
Prestwick_731
Pulminiq
Ramihyphin A
Restasis
Restasis (TN)
S-Neoral
S1514_Selleck
SDZ-OXL 400
SMR000058578
SPBio_001467
SPECTRUM1502202
ST-603
Sandimmun
Sandimmun Neoral
Sandimmune
Sandimmune (TN)
Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine
Sang-2000
Sang-35
SangCyA
Sangcya
Sigmasporin
Sigmasporin Microoral
Spectrum2_001484
Spectrum3_001593
Spectrum4_001279
Spectrum5_001628
Spectrum_000300
TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)
Vekacia
Zyclorin
cyclophorine
cyclosporin A
cyclosporine
from Tolypocladium inflatum (Trichoderma polysporin)
nchembio.184-comp6
nchembio.301-comp5
nchembio.342-comp1
32
Bortezomibapproved, investigationalPhase 2794179324-69-7387447, 93860
Synonyms:
179324-69-7
AC1L8TUW
Bortezomib
Bortezomib (JAN/USAN/INN)
CHEBI:287372
CHEBI:41143
CHEMBL325041
CID387447
D03150
DB07475
DPBA
FT-0082488
I14-3268
LDP-341
LDP341
LPD 341
LPD-341
 
MLN341
MolPort-003-845-298
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
NCI60_029010
NSC-681239
NSC681239
PROSCRIPT BORONIC ACID
PS-341
Pyz-Phe-boroLeu
S1013_Selleck
SBB071337
Velcade
Velcade (TN)
Velcade, MG-341, PS-341, Bortezomib
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
bortezomib
33
DeferiproneapprovedPhase 25730652-11-02972
Synonyms:
1,2-Dimethyl-3-hydroxypyrid-4-one
3-Hydroxy-1,2-dimethyl-4(1H)-pyridone
APO-066
CP-20
DN-180-01-AF
Deferipron
 
Deferiprona
Deferiproni
Deferipronum
Deferypron
Dimethylhydroxypyridone
Défériprone
Ferriprox
PL-1
34
Deferoxamineapproved, investigationalPhase 24570-51-92973
Synonyms:
DF B
DFO
DFOA
DFOM
Deferoxamide B
Deferoxamin
Deferoxamina
 
Deferoxamine B
Deferoxaminum
Deferrioxamine
Deferrioxamine B
Deferrioxamine b
Desferrioxamine
Desferrioxamine B
Déferoxamine
N-Benzoylferrioxamine B
35
Tacrolimusapproved, investigationalPhase 2, Phase 11074104987-11-3445643, 439492
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
 
FR900506
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus anhydrous
Tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
36
ThiotepaapprovedPhase 2, Phase 121652-24-45453
Synonyms:
 
Thioplex
37
FosphenytoinapprovedPhase 1, Phase 21193390-81-956339
Synonyms:
(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl dihydrogen phosphate
(3-Phosphoryloxymethyl)phenytoin
3-(hydroxymethyl)phenytoin disodium phosphate
3-(hydroxymethyl)phenytoin phosphate ester
92134-98-0 (di-hydrochloride salt)
93390-81-9
AC1L1KUO
AC1Q6NQH
ACC-9653
BIDD:GT0220
C07840
CID56339
Cerebyx
D07993
DB01320
Fosfenitoina
 
Fosfenitoina [INN-Spanish]
Fosfenitoina [inn-spanish]
Fosphenytoin
Fosphenytoin (INN)
Fosphenytoin [INN:BAN]
Fosphenytoine
Fosphenytoine [INN-French]
Fosphenytoine [inn-french]
Fosphenytoinum
Fosphenytoinum [INN-Latin]
Fosphenytoinum [inn-latin]
HMPDP
HSDB 7523
LS-178209
LS-187339
Prodilantin
UNII-B4SF212641
38
Phenytoinapproved, vet_approvedPhase 1, Phase 27657-41-01775
Synonyms:
125-59-7
2,4-Imidazolidinedione, 5,5-diphenyl- (9CI)
2-hydroxy-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one
5,5-DIPHENYLHYDANTOIN
5,5-Diphenyl-2,4-imidazolidinedione
5,5-Diphenyl-imidazolidine-2,4-dione
5,5-Diphenylhydantoin
5,5-Diphenylhydantoin (IUPAC)
5,5-Diphenylhydantoin (phenytoin)
5,5-Diphenylimidazolidin-2,4-dione
5,5-Diphenyltetrahydro-1H-2,4-imidazoledione
5,5-Dwufenylohydantoina
5,5-Dwufenylohydantoina [Polish]
5,5-diphenylhydantoin
5,5-diphenylimidazolidine-2,4-dione
5,5-diphenyltetrahydro-1H-2,4-imidazoledione
57-41-0
630-93-3
AC-376
AC1L1C7L
AC1Q6G55
AC1Q6G56
AI3-52498
AKOS000416887
AKOS003245432
Aleviatin
Antisacer
Auranile
BAS 00281572
BIDD:GT0625
BIDD:PXR0090
BRD-K55930204-001-02-7
BSPBio_001437
Bio-0370
C07443
CCRIS 515
CHEBI:8107
CHEMBL16
CID1775
CL12003
Causoin
Citrullamon
Citrulliamon
Comital
Comitoina
Convul
D 4007
D00512
D0894
D4007_SIGMA
DB00252
DILANTIN-30
DPH
DPH (VAN)
Danten
Dantinal
Dantoinal
Dantoinal klinos
Dantoine
Denyl
Di-Hydan
Di-Lan
Di-Lan (VAN)
Di-Phetine
Didan TDC 250
Didan-tdc-250
Difenilhidantoina
Difenilhidantoina [Spanish]
Difenin
Difetoin
Difhydan
Dihycon
Dihydan toin
Dihydantoin
Dilabid
Dilantin
Dilantin (TN)
Dilantin acid
Dilantin-125
Dilantine
Dillantin
Dintoin
Dintoina
Diphantoin
Diphedal
Diphedan
Diphenat
Diphenin
Diphenine
Diphentoin
Diphentyn
Diphenylan
Diphenylan Sodium
Diphenylhydantoin
Diphenylhydantoin (VAN)
Diphenylhydantoine
Diphenylhydantoine [French]
Diphenylhydatanoin
Ditoinate
DivK1c_000507
EINECS 200-328-6
EU-0100378
Ekko
Ekko capsules
Elepsindon
Enkelfel
Epamin
Epanutin
Epasmir "5"
Epasmir 5
Epdantoin Simple
Epdantoine simple
Epelin
Epifenyl
Epihydan
Epilan
Epilan D
Epilan-D
Epilantin
Epinat
Epised
Eptal
Eptoin
Extended Phenytoin Sodium
Fenantoin
Fenantoin Mn Pharma
Fenidantoin "s"
Fenidantoin s
Fenitoin
Fenitoina
Fenitoina [INN-Spanish]
Fentoin
Fenylepsin
Fenytoin Dak
Fenytoine
Gerot-epilan-D
HMS1412J16
 
HMS1694O05
HMS1791H19
HMS1989H19
HMS2089E11
Hidan
Hidantal
Hidantilo
Hidantina
Hidantina senosian
Hidantina vitoria
Hidantomin
Hindatal
Hydantal
Hydantin
Hydantoin
Hydantoin, 5,5-diphenyl- (8CI)
Hydantoinal
Hydantol
I14-6452
IDI1_000507
IDI1_008433
IFLab1_000214
Ictalis simple
Idantoil
Idantoin
InChI=1/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19
Iphenylhydantoin
KBio1_000507
KBio2_001585
KBio2_004153
KBio2_006721
KBio3_001780
KBioGR_001387
KBioSS_001585
Kessodanten
LS-34
Labopal
Lehydan
Lepitoin
Lepsin
Lopac-D-4007
Lopac0_000329
Lopac0_000378
MLS000069789
MLS001074087
MLS002454401
Mesantoin
Minetoin
MolPort-001-785-683
MolPort-002-365-712
MolPort-004-876-351
NCGC00015342-01
NCGC00015342-02
NCGC00015342-04
NCGC00021139-01
NCGC00091492-01
NCGC00091492-02
NCGC00091492-03
NCGC00091492-04
NCGC00091492-05
NCGC00093810-01
NCGC00093810-02
NCI-C55765
NINDS_000507
NSC 8722
NSC8722
Neos-Hidantoina
Neosidantoina
Novantoina
Novophenytoin
Om hidantoina simple
Om-Hydantoine
Oprea1_373280
Oxylan
PHENYTEK
PHENYTOIN (5,5-DIPHENYLHYDANTOIN)
PHENYTOIN SODIUM, EXTENDED
Phanantin
Phanatine
Phenatine
Phenatoine
Phenhydan
Phenhydanin
Phenitoin
Phentoin
Phentytoin
Phenytex
Phenytoin (JP15/USP/INN)
Phenytoin AWD
Phenytoin Sodium
Phenytoin [USAN:INN:BAN:JAN]
Phenytoin-Gerot
Phenytoine
Phenytoine [INN-French]
Phenytoinum
Phenytoinum [INN-Latin]
Prompt Phenytoin Sodium
Ritmenal
SMR000059026
SPBio_001281
STK058029
STK182871
Saceril
Sanepil
Silantin
Sinergina
Sodanthon
Sodantoin
Sodanton
Sodium Diphenylhydantoinate
Solantin
Solantoin
Solantyl
Spectrum2_001281
Spectrum3_000890
Spectrum4_000984
Spectrum5_001369
Spectrum_001105
Sylantoic
TOIN
Tacosal
Thilophenyl
Toin unicelles
UNII-6158TKW0C5
WLN: T5MVMV EHJ ER& ER
ZINC02510358
ZINC18140189
Zentronal
Zentropil
component of Mebroin
elepsi ndon
epasmir ''5''
fen toin
fenidantoin ''s''
ictalis simp le
phenat ine
phenytoin
phenytoin (PHN)
taco sal
39
DanazolapprovedPhase 1, Phase 21617230-88-528417
Synonyms:
(17a)-Pregna-2,4-dien-20-yno[2,3-D]isoxazol-17-ol
(1R,3aS,3bR,10aR,10bS,12aS)-1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol
(1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5,9-trien-17-ol
1-Ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol
1-Ethynyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-10a,12a-dimethyl-1H-Cyclopenta[7,8]phenanthro[3,2-D]isoxazol-1-ol
17 alpha-Pregna-2,4-dien-20-yno[2,3-D] isoxazol-17 beta-ol
17-alpha-2,4-Pregnadien-20-yno(2,3-d)isoxazol-17-ol
17-alpha-Pregn-4-en-20-yno(2,3-d)isoxazol-17-ol
17-alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol
17.Alpha.-Pregna-2, {4-dien-20-yno[2,3-d]isoxazol-17-ol}
17230-88-5
17a-Pregna-2,4-dien-20-yne-[2,3-D]isoxazole-17b-ol
17a-Pregna-2,4-dien-20-yno[2,3-D]isoxazol-17-ol
17alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol
1H-Cyclopenta[7,8]phenanthro[3,2-D]isoxazole- pregna-2,4-dien-20-yno[2,3-D]isoxazol-17-ol deriv.
AC-6836
AC1L1FAD
AC1Q282K
AC1Q29FD
Alphapharm Brand of Danazol
Antigen Brand of Danazol
BPBio1_000100
BRD-K48970916-001-03-0
BSPBio_000090
Bonzol
CCRIS 6747
CHEBI:4315
CHEMBL1479
CID28417
CPD000058321
Chronogyn
Cyclomen
D00289
D003613
DB01406
Danatrol
Danazant
Danazol (JAN/USP/INN)
Danazol [USAN:BAN:INN:JAN]
Danazol-ratiopharm
Danazole
Danazolum
Danazolum [INN-Latin]
Danocrine
 
Danocrine (TN)
Danogen
Danokrin
Danol
Danoval
Danovaol
Danzol
EINECS 241-270-1
HMS1568E12
HMS2090A22
Kendrick Brand of Danazol
LS-118524
Ladogal
MLS001066617
MLS001306473
MolPort-002-513-504
NCGC00164400-01
NCGC00179665-01
NSC 270916
NSC270916
Norciden
Panacrine
Prestwick0_000105
Prestwick1_000105
Prestwick2_000105
Prestwick3_000105
Prestwick_150
SAM002564203
SMR000058321
SPBio_002029
STOCK1N-23495
Sanofi Brand of Danazol
Sanofi Synthelabo Brand of Danazol
Sanofi Winthrop Brand of Danazol
UNII-N29QWW3BUO
WIN 17,757
WIN 17757
WIN-17757
Win 17, 757
Winobanin
ZINC03881958
[1,2]oxazolo[4',5':2,3]-17alpha-pregn-4-en-20-yn-17-ol
anatrol
danazol
ratiopharm Brand of Danazol
40Prednisolone acetatePhase 2, Phase 11153
41Prednisolone hemisuccinatePhase 2, Phase 11153
42Prednisolone phosphatePhase 2, Phase 11153
43Protective AgentsPhase 2, Phase 17190
44Antilymphocyte SerumPhase 2, Phase 1399
45Autonomic AgentsPhase 2, Phase 19774
46Gastrointestinal AgentsPhase 2, Phase 18109
47Antineoplastic Agents, HormonalPhase 2, Phase 15407
48Anti-Inflammatory AgentsPhase 2, Phase 110355
49AntiemeticsPhase 2, Phase 13888
50glucocorticoidsPhase 2, Phase 14920

Interventional clinical trials:

(show top 50)    (show all 79)
idNameStatusNCT IDPhase
1Fanconi Syndrome Due to ARVs in HIV-Infected PersonsCompletedNCT00499187Phase 4
2Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant DiseasesUnknown statusNCT01019876Phase 2, Phase 3
3Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With CystinosisCompletedNCT01000961Phase 3
4A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron OverloadCompletedNCT00171821Phase 3
5TBI Dose De-escalation for Fanconi AnemiaRecruitingNCT00352976Phase 2, Phase 3
6Fanconi Anemia Transplant Lacking Genotypically Identical DonorUnknown statusNCT00850317Phase 2
7Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant DiseasesUnknown statusNCT00084695Phase 2
8Multicenter Transplant Study for Fanconi AnemiaCompletedNCT01082133Phase 2
9Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100CompletedNCT00479115Phase 1, Phase 2
10Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's AnemiaCompletedNCT00005898Phase 1, Phase 2
11Medical Treatment for Diamond Blackfan AnemiaCompletedNCT00001749Phase 2
12Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic AnemiasCompletedNCT00061763Phase 2
13Phase II Pilot Study of Granulocyte Colony-Stimulating Factor for Inherited Bone Marrow Failure SyndromesCompletedNCT00004787Phase 2
14Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell TransplantsCompletedNCT00307086Phase 2
15Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First RemiCompletedNCT00305708Phase 1, Phase 2
16Cord Blood Stem Cell Transplantation Study (COBLT)CompletedNCT00000603Phase 2
17Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With CystinosisCompletedNCT00872729Phase 1, Phase 2
18A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe ToxicityCompletedNCT01044186Phase 2
19Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi AnemiaRecruitingNCT00258427Phase 2
20Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi AnemiaRecruitingNCT00630253Phase 1, Phase 2
21Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and PlerixaforRecruitingNCT02678533Phase 1, Phase 2
22Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1RecruitingNCT02931071Phase 2
23HSCT for Patients With Fanconi Anemia Using Risk-Adjusted ChemotherapyRecruitingNCT02143830Phase 2
24Talazoparib Beyond BRCA (TBB) TrialRecruitingNCT02401347Phase 2
25A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair DeficiencyRecruitingNCT02873975Phase 2
26Hematopoietic Stem Cell Transplant for Fanconi AnemiaActive, not recruitingNCT01071239Phase 2
27Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi AnemiaActive, not recruitingNCT00453388Phase 2
28Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and FludarabineActive, not recruitingNCT00987480Phase 2
29Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell TransplantationActive, not recruitingNCT01690143Phase 1, Phase 2
30CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor TransplantActive, not recruitingNCT01049854Phase 2
31Phase II Study of BMN 673Active, not recruitingNCT02286687Phase 2
32Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis CongenitaTerminatedNCT01001598Phase 1, Phase 2
33Stem Cell Transplantation for Fanconi AnemiaTerminatedNCT00167206Phase 1, Phase 2
34Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi AnemiaTerminatedNCT00590460Phase 1, Phase 2
35Stem Cell Transplant for Hematologic DiseasesTerminatedNCT00058825Phase 1, Phase 2
36Double Cord Blood TransplantationTerminatedNCT00801931Phase 1, Phase 2
37Phase I Study of Amifostine in Patients With Bone Marrow Failure Related to Fanconi's AnemiaUnknown statusNCT00006127Phase 1
38Phase I Pilot Study of CD34 Enriched, Fanconi's Anemia Complementation Group C Gene Transduced Autologous Peripheral Blood Stem Cell Transplantation in Patients With Fanconi's AnemiaUnknown statusNCT00005896Phase 1
39Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi AnemiaCompletedNCT00243399Phase 1
40Cyclophosphamide in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Fanconi's AnemiaCompletedNCT00317876Phase 1
41Bone Marrow Cell Gene Transfer in Individuals With Fanconi AnemiaCompletedNCT00272857Phase 1
42Gene Therapy for the Treatment of Fanconi's Anemia Type CCompletedNCT00001399Phase 1
43Quercetin in Children With Fanconi Anemia; a Pilot StudyRecruitingNCT01720147Phase 1
44Gene Therapy for Fanconi AnemiaRecruitingNCT01331018Phase 1
45BMT Abatacept for Non-Malignant DiseasesRecruitingNCT01917708Phase 1
46Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant DiseasesRecruitingNCT02231710Phase 1
47Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi AnemiaActive, not recruitingNCT00093743Phase 1
48Diagnostic Aids for Detection and Diagnosis of Oral CancerActive, not recruitingNCT02251639Phase 1
49Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCTTerminatedNCT00586274Phase 1
50Study of Fludarabine Drug Exposure in Pediatric Bone Marrow TransplantationUnknown statusNCT01316549

Search NIH Clinical Center for Fanconi Anemia, Complementation Group a

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Genetic Tests for Fanconi Anemia, Complementation Group a

About this section

Genetic tests related to Fanconi Anemia, Complementation Group a:

id Genetic test Affiliating Genes
1 Fanconi Anemia, Complementation Group a26
2 Fanconi Anemia26 24

Anatomical Context for Fanconi Anemia, Complementation Group a

About this section

MalaCards organs/tissues related to Fanconi Anemia, Complementation Group a:

35
Bone, Bone marrow, Kidney, Skin, Myeloid, Uterus, Hypothalamus

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Fanconi Anemia, Complementation Group a:
id TissueAnatomical CompartmentCell Relevance
1 BloodHematopoietic Bone MarrowHematopoietic Stem Cells Potential therapeutic candidate

Animal Models for Fanconi Anemia, Complementation Group a or affiliated genes

About this section

MGI Mouse Phenotypes related to Fanconi Anemia, Complementation Group a:

40 (show all 14)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000538010.9ATM, BRCA1, BRCA2, FANCA, FANCL, PALB2
2MP:000200610.9ATM, BRCA1, BRCA2, BRIP1, FANCA, FANCD2
3MP:000537910.7ATM, BRCA1, BRCA2, BRIP1, FANCA, FANCB
4MP:000537810.7ATM, BRCA1, BRCA2, ERCC4, FANCA, FANCB
5MP:000538910.6ATM, BRCA1, BRCA2, BRIP1, FANCA, FANCB
6MP:001076810.6ATM, BRCA1, BRCA2, ERCC4, FANCA, FANCD2
7MP:000538410.6ATM, BRCA1, BRCA2, BRIP1, ERCC4, FANCA

Publications for Fanconi Anemia, Complementation Group a

About this section

Articles related to Fanconi Anemia, Complementation Group a:

(show all 15)
idTitleAuthorsYear
1
p38 mitogen-activated protein kinase inhibition enhances inA vitro erythropoiesis of Fanconi anemia, complementation group A-deficient boneA marrow cells. (25534205)
2015
2
Human Fanconi Anemia Complementation Group A Protein Stimulates the 5' Flap Endonuclease Activity of FEN1. (24349332)
2013
3
Damage-dependent regulation of MUS81-EME1 by Fanconi anemia complementation group A protein. (24170812)
2013
4
Changes in vimentin, lamin A/C and mitofilin induceA aberrant cell organization in fibroblasts from Fanconi anemia complementation group A (FA-A) patients. (23831462)
2013
5
Mitochondrial respiratory chain Complex I defects in Fanconi anemia complementation group A. (23791750)
2013
6
Fanconi anemia complementation group A (FANCA) protein has intrinsic affinity for nucleic acids with preference for single-stranded forms. (22194614)
2012
7
Validation of Fanconi anemia complementation Group A assignment using molecular analysis. (19367192)
2009
8
Fanconi anemia complementation group A cells are hypersensitive to chromium(VI)-induced toxicity. (12426130)
2002
9
Functional analysis of the putative peroxidase domain of FANCA, the Fanconi anemia complementation group A protein. (11161829)
2001
10
Fanconi anemia, complementation group A, cells are defective in ability to produce incisions at sites of psoralen interstrand cross-links. (10753211)
2000
11
SNX5, a new member of the sorting nexin family, binds to the Fanconi anemia complementation group A protein. (10600472)
1999
12
Intracellular localization of the Fanconi anemia complementation group A protein. (10364463)
1999
13
A deficiency in a 230 kDa DNA repair protein in fanconi anemia complementation group A cells is corrected by the FANCA cDNA. (10469633)
1999
14
The Fanconi anemia complementation group A protein contains a peroxidase domain. (9608546)
1998
15
A damage-recognition protein which binds to DNA containing interstrand cross-links is absent or defective in Fanconi anemia, complementation group A, cells. (8414972)
1993

Variations for Fanconi Anemia, Complementation Group a

About this section

UniProtKB/Swiss-Prot genetic disease variations for Fanconi Anemia, Complementation Group a:

69 (show all 29)
id Symbol AA change Variation ID SNP ID
1FANCAp.Ala181ValVAR_009639rs17232246
2FANCAp.Leu244PheVAR_009640
3FANCAp.Asp252GlyVAR_009641rs17225943
4FANCAp.Arg435CysVAR_009642rs148473140
5FANCAp.His492ArgVAR_009643
6FANCAp.Leu817ProVAR_009647
7FANCAp.Leu845ProVAR_009648
8FANCAp.Arg1055LeuVAR_009649
9FANCAp.His1110ProVAR_009650
10FANCAp.Arg1117GlyVAR_009651rs149277003
11FANCAp.Gln1128GluVAR_009652
12FANCAp.Thr1131AlaVAR_009653rs574034197
13FANCAp.Trp1302ArgVAR_009656
14FANCAp.His1417AspVAR_009658rs17227403
15FANCAp.Asp598AsnVAR_017497
16FANCAp.Ser858ArgVAR_017498rs17233141
17FANCAp.Arg1055TrpVAR_017499rs753063086
18FANCAp.Leu1082ProVAR_017500
19FANCAp.Ser1088PheVAR_017501rs17233497
20FANCAp.Phe1262LeuVAR_017502
21FANCAp.Asp1359TyrVAR_017503
22FANCAp.Met1360IleVAR_017504
23FANCAp.Pro1324LeuVAR_017505rs182657062
24FANCAp.Leu210ArgVAR_038012
25FANCAp.Leu660ProVAR_038013
26FANCAp.Tyr843AspVAR_038015rs374030577
27FANCAp.Gln869ProVAR_038016rs780825099
28FANCAp.Leu1249ProVAR_038019rs753316789
29FANCAp.Arg1400HisVAR_038021rs149851163

Clinvar genetic disease variations for Fanconi Anemia, Complementation Group a:

5 (show all 55)
id Gene Variation Type Significance SNP ID Assembly Location
1FANCCNM_000136.2(FANCC): c.456+4A> TSNVPathogenicrs104886456GRCh37Chr 9, 97934315: 97934315
2FANCCNM_000136.2(FANCC): c.1642C> T (p.Arg548Ter)SNVPathogenicrs104886457GRCh37Chr 9, 97864024: 97864024
3FANCCNM_000136.2(FANCC): c.355_360delTCTCATinsA (p.Ser119Asnfs)indelPathogenicrs587779904GRCh37Chr 9, 97934415: 97934420
4FANCCNM_000136.2(FANCC): c.843+1G> ASNVLikely pathogenic, Pathogenicrs587779909GRCh37Chr 9, 97897627: 97897627
5FANCANM_000135.2(FANCA): c.3066+1G> TSNVPathogenicrs587783028GRCh38Chr 16, 89752137: 89752137
6FANCCNM_000136.2(FANCC): c.1302dupT (p.Gly435Trpfs)duplicationPathogenicrs730881709GRCh38Chr 9, 95111490: 95111490
7FANCANM_000135.2(FANCA): c.283+3A> CSNVPathogenicrs786204204GRCh38Chr 16, 89814517: 89814517
8FANCANM_000135.2(FANCA): c.97delG (p.Glu33Lysfs)deletionPathogenicrs786204238GRCh38Chr 16, 89815969: 89815969
9FANCANM_000135.2(FANCA): c.2839dupT (p.Ser947Phefs)duplicationLikely pathogenic, Pathogenicrs756367276GRCh38Chr 16, 89761962: 89761962
10FANCANM_000135.2(FANCA): c.3403_3405delTTC (p.Phe1135del)deletionPathogenicrs786204246GRCh37Chr 16, 89813242: 89813244
11FANCANM_000135.2(FANCA): c.2557C> T (p.Arg853Ter)SNVPathogenicrs752160950GRCh38Chr 16, 89767185: 89767185
12FANCAFANCA, IVS7DS, G-A, +5SNVPathogenicChr na, -1: -1
13FANCANM_000135.2(FANCA): c.2762A> T (p.Lys921Ile)SNVLikely pathogenicrs879255255GRCh38Chr 16, 89764906: 89764906
14FANCANM_000135.2(FANCA): c.987_990delTCAC (p.His330Alafs)deletionPathogenicrs772359099GRCh38Chr 16, 89795922: 89795925
15FANCANM_000135.2(FANCA): c.4015delC (p.Leu1339Serfs)deletionLikely pathogenicrs762902309GRCh37Chr 16, 89805693: 89805693
16BRCA1NM_007294.3(BRCA1): c.594_597delTGTG (p.Ser198Argfs)deletionPathogenicrs797045175GRCh38Chr 17, 43095919: 43095922
17FANCLNM_018062.3(FANCL): c.1096_1099dupATTA (p.Thr367Asnfs)duplicationPathogenicrs759217526GRCh38Chr 2, 58159794: 58159797
18FANCANM_000135.2(FANCA): c.(?_-1)_522+?deldeletionPathogenicGRCh38Chr 16, 89810707: 89816616
19FANCCNM_000136.2(FANCC): c.489_490delGA (p.Asn164Serfs)deletionPathogenicrs863224470GRCh37Chr 9, 97933392: 97933393
20FANCGNM_004629.1(FANCG): c.156dupG (p.Leu53Alafs)duplicationPathogenicrs863224506GRCh37Chr 9, 35079167: 35079167
21FANCANM_000135.2(FANCA): c.238delT (p.Cys80Valfs)deletionPathogenicrs864622187GRCh37Chr 16, 89880973: 89880973
22FANCANM_000135.2(FANCA): c.416_417delTG (p.Val139Glyfs)deletionPathogenicrs864622188GRCh38Chr 16, 89810938: 89810939
23FANCINM_001113378.1(FANCI): c.3623_3624delTG (p.Cys1209Leufs)deletionPathogenicrs770318990GRCh37Chr 15, 89850875: 89850876
24FANCCNM_000136.2(FANCC): c.997-?_1154+?deldeletionPathogenicChr na, -1: -1
25FANCCNM_000136.2(FANCC): c.1290C> A (p.Tyr430Ter)SNVLikely pathogenic, Pathogenicrs766105286GRCh37Chr 9, 97873784: 97873784
26FANCANM_000135.2(FANCA): c.3349A> G (p.Arg1117Gly)SNVPathogenicrs149277003GRCh37Chr 16, 89813298: 89813298
27FANCANM_000135.2(FANCA): c.4069_4082delGCTGTGGACATGTA (p.Ala1357Leufs)deletionPathogenicrs747892390GRCh38Chr 16, 89739218: 89739231
28FANCANM_000135.2(FANCA): c.1074_1075delGT (p.Tyr359Profs)deletionPathogenicrs878853660GRCh37Chr 16, 89858887: 89858888
29FANCANM_000135.2(FANCA): c.2730_2731delCT (p.Trp911Aspfs)deletionPathogenicrs878853663GRCh38Chr 16, 89764937: 89764938
30FANCANM_000135.2(FANCA): c.3391A> G (p.Thr1131Ala)SNVPathogenicrs574034197GRCh37Chr 16, 89813256: 89813256
31FANCCNM_000136.2(FANCC): c.-78-?_250+?deldeletionPathogenicChr na, -1: -1
32FANCCNM_000136.2(FANCC): c.29dupG (p.Cys10Trpfs)duplicationPathogenicrs878853671GRCh37Chr 9, 98011545: 98011545
33FANCINM_001113378.1(FANCI): c.507G> A (p.Trp169Ter)SNVPathogenicrs878854181GRCh38Chr 15, 89263422: 89263422
34FANCLNM_018062.3(FANCL): c.426_438delTGCTTCTGGTAGA (p.Asp142Glufs)deletionPathogenicrs878855046GRCh38Chr 2, 58204163: 58204175
35SLX4NM_032444.2(SLX4): c.3726_3729delGAGC (p.Ser1243Alafs)deletionPathogenicrs878855162GRCh38Chr 16, 3589909: 3589912
36FANCD2NM_033084.4(FANCD2): c.2444G> A (p.Arg815Gln)SNVPathogenicrs766567785GRCh38Chr 3, 10067267: 10067267
37FANCD2NM_033084.4(FANCD2): c.-33-?_1098+?deldeletionPathogenicChr na, -1: -1
38FANCANM_000135.2: c.1627_1900del274deletionPathogenicChr na, -1: -1
39FANCANM_000135.2(FANCA): c.1115_1118delTTGG (p.Val372Alafs)deletionPathogenicrs397507552GRCh37Chr 16, 89858442: 89858445
40FANCAFANCA, 156-BP DEL, NT1515deletionPathogenicChr na, -1: -1
41FANCANM_000135.2(FANCA): c.894_1006del113 (p.Trp298Cysfs)deletionPathogenicChr na, -1: -1
42FANCANM_000135.2(FANCA): c.1615delG (p.Asp539Thrfs)deletionPathogenicrs778507965GRCh38Chr 16, 89782870: 89782870
43FANCANM_000135.2(FANCA): c.3558dupG (p.Arg1187Glufs)duplicationPathogenicrs747851434GRCh38Chr 16, 89745027: 89745027
44FANCANM_000135.2(FANCA): c.1007_3066deldeletionPathogenicGRCh38Chr 16, 89751224: 89795381
45FANCANM_000135.2(FANCA): c.1606delT (p.Ser536Glnfs)deletionPathogenicrs587776570GRCh38Chr 16, 89782879: 89782879
46FANCANM_000135.2(FANCA): c.513G> A (p.Trp171Ter)SNVPathogenicrs121907930GRCh37Chr 16, 89877124: 89877124
47FANCANM_000135.2(FANCA): c.3720_3724delAAACA (p.Glu1240Aspfs)deletionPathogenicrs794726660GRCh38Chr 16, 89742841: 89742845
48FANCANM_000135.2: c.295C> TSNVPathogenicChr na, -1: -1
49FANCANM_000135.2: c.3761_3762delAGdeletionPathogenicChr na, -1: -1
50FANCANM_000135.2: c.811C> TSNVLikely pathogenicChr na, -1: -1
51FANCANM_000135.2: c.154C> TSNVPathogenicChr na, -1: -1
52FANCANM_000135.2(FANCA): c.3788_3790delTCT (p.Phe1263del)deletionPathogenicrs397507553GRCh37Chr 16, 89807250: 89807252
53BRIP1NM_032043.2(BRIP1): c.2392C> T (p.Arg798Ter)SNVPathogenicrs137852986GRCh37Chr 17, 59793412: 59793412
54BRCA1NM_007294.3(BRCA1): c.5095C> T (p.Arg1699Trp)SNVPathogenicrs55770810GRCh37Chr 17, 41215948: 41215948
55FANCFNM_022725.3(FANCF): c.484_485delCT (p.Leu162Aspfs)deletionLikely pathogenic, Pathogenicrs587778340GRCh37Chr 11, 22646872: 22646873

Copy number variations for Fanconi Anemia, Complementation Group a from CNVD:

6
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1106526168870000090354753Copy numberFANCAFanconi anemia

Expression for genes affiliated with Fanconi Anemia, Complementation Group a

About this section
Search GEO for disease gene expression data for Fanconi Anemia, Complementation Group a.

Pathways for genes affiliated with Fanconi Anemia, Complementation Group a

About this section

Pathways related to Fanconi Anemia, Complementation Group a according to GeneCards Suite gene sharing:

(show all 15)
idSuper pathwaysScoreTop Affiliating Genes
110.4ATM, BRCA1
210.3ATM, BRCA1, FANCD2, FANCL
3
Show member pathways
10.3ATM, BRCA1, FANCD2, RAD51
410.2ATM, BRCA1, BRCA2, RAD51
510.2ATM, BRCA1, BRCA2, RAD51
6
Show member pathways
10.2ATM, BRCA1, BRIP1, FANCC, FANCD2, FANCI
7
Show member pathways
10.2ATM, BRCA1, BRCA2, RAD51, RAD51C
8
Show member pathways
10.1ATM, BRCA1, BRCA2, BRIP1, FANCD2, FANCL
910.1ATM, BRCA1, BRIP1, ERCC4, FANCA, FANCB
1010.0ATM, BRCA1, FANCA, FANCC, FANCD2, FANCE
11
Show member pathways
10.0ATM, BRCA1, BRCA2, BRIP1, ERCC4, PALB2
12
Show member pathways
10.0ATM, BRCA1, BRCA2, FANCA, FANCC, FANCD2
13
Show member pathways
9.9ATM, BRCA1, BRCA2, ERCC4, FANCA, FANCC
14
Show member pathways
9.6BRCA1, BRCA2, BRIP1, ERCC4, FANCA, FANCB
15
Show member pathways
9.5ATM, BRCA1, BRCA2, BRIP1, ERCC4, FANCA

GO Terms for genes affiliated with Fanconi Anemia, Complementation Group a

About this section

Cellular components related to Fanconi Anemia, Complementation Group a according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1ERCC4-ERCC1 complexGO:007052211.2ERCC4, SLX4
2Holliday junction resolvase complexGO:004847611.1RAD51C, SLX4
3condensed chromosomeGO:000079311.0BRCA1, FANCD2, RAD51
4condensed nuclear chromosomeGO:000079410.8BRCA1, RAD51, RAD51C
5Fanconi anaemia nuclear complexGO:004324010.8FANCA, FANCB, FANCC, FANCE, FANCF, FANCG
6nuclear chromosome, telomeric regionGO:000078410.7ATM, BRCA2, ERCC4, RAD51, SLX4
7cytoplasmGO:00057379.5ATM, BRCA1, BRCA2, BRIP1, FANCA, FANCC
8nucleoplasmGO:00056549.5ATM, BRCA1, BRCA2, BRIP1, ERCC4, FANCA

Biological processes related to Fanconi Anemia, Complementation Group a according to GeneCards Suite gene sharing:

(show all 32)
idNameGO IDScoreTop Affiliating Genes
1regulation of CD40 signaling pathwayGO:200034811.1FANCA, FANCD2
2protein K6-linked ubiquitinationGO:008502011.0BRCA1, UBE2T
3mitotic recombination-dependent replication fork processingGO:199042610.9BRCA2, RAD51
4chordate embryonic developmentGO:004300910.9BRCA1, BRCA2
5DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:000697810.9BRCA1, BRCA2
6chromosome breakageGO:003105210.9BRCA1, BRCA2, PALB2
7inner cell mass cell proliferationGO:000183310.9BRCA2, PALB2
8resolution of meiotic recombination intermediatesGO:000071210.9ERCC4, FANCM
9cellular response to gamma radiationGO:007148010.8ATM, RAD51
10female gonad developmentGO:000858510.8BRCA2, FANCA
11intrinsic apoptotic signaling pathway in response to DNA damageGO:000863010.8ATM, BRCA1, BRCA2
12double-strand break repairGO:000630210.7BRCA1, BRCA2, BRIP1
13DNA double-strand break processingGO:000072910.7ATM, BRCA1
14nucleotide-excision repairGO:000628910.7BRCA2, ERCC4, FANCC, SLX4
15regulation of signal transduction by p53 class mediatorGO:190179610.6ATM, BRCA1, BRIP1
16telomere maintenance via recombinationGO:000072210.6BRCA2, RAD51, RAD51C
17male meiosis IGO:000714110.6BRCA2, RAD51C
18double-strand break repair via homologous recombinationGO:000072410.6ATM, BRCA1, BRCA2, ERCC4, PALB2, RAD51
19chromosome organization involved in meiotic cell cycleGO:007019210.6RAD51, RAD51C
20DNA replicationGO:000626010.6ATM, BRCA1, BRIP1, SLX4
21mitotic recombinationGO:000631210.6RAD51, RAD51C
22strand invasionGO:004214810.6RAD51, RAD51C
23gamete generationGO:000727610.5FANCD2, FANCL
24DNA recombinase assemblyGO:000073010.5RAD51, RAD51C
25reciprocal meiotic recombinationGO:000713110.5ATM, RAD51, RAD51C
26DNA synthesis involved in DNA repairGO:000073110.4ATM, BRCA1, BRCA2, BRIP1, PALB2, RAD51
27strand displacementGO:000073210.4ATM, BRCA1, BRCA2, BRIP1, PALB2, RAD51
28regulation of regulatory T cell differentiationGO:004558910.4FANCA, FANCD2
29cellular response to DNA damage stimulusGO:000697410.4ATM, BRCA1, BRCA2, FANCD2, FANCF, FANCG
30interstrand cross-link repairGO:003629710.3ERCC4, FANCA, FANCB, FANCC, FANCD2, FANCE
31response to ionizing radiationGO:001021210.0ATM, BRCA1, RAD51C
32DNA repairGO:000628110.0ATM, ERCC4, FANCA, FANCC, FANCG, FANCL

Molecular functions related to Fanconi Anemia, Complementation Group a according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1crossover junction endodeoxyribonuclease activityGO:000882111.1RAD51C, SLX4
2DNA polymerase bindingGO:007018211.0FANCD2, FANCI, RAD51
3damaged DNA bindingGO:000368410.9BRCA1, ERCC4, FANCG
4recombinase activityGO:000015010.8RAD51, RAD51C
5four-way junction DNA bindingGO:000040010.8RAD51, RAD51C
6endodeoxyribonuclease activityGO:000452010.8ERCC4, RAD51, SLX4
7single-stranded DNA bindingGO:000369710.7BRCA2, ERCC4, RAD51, RAD51C
8protein bindingGO:00055159.6ATM, BRCA1, BRCA2, BRIP1, ERCC4, FANCA

Sources for Fanconi Anemia, Complementation Group a

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet